The BioCentury 100 index rose only 2% in 2Q14, while the NYSE Arca Biotechnology (BTK) and NASDAQ Biotechnology (NBI) indices both gained more than 7%. The discrepancy is largely due to big downturns of stocks included in the BC100 that are not in